Eli Lilly Jaypirca Approval +6.8% as CHMP Backs CLL Use
Can Eli Lilly Jaypirca Approval turn a regulatory win into a lasting oncology growth engine for investors?
Pfizer Lung Cancer Trial Sends Warning on Oncology Pivot
Can Pfizer’s lung cancer setback stay contained to one trial, or is it an early warning for its broader oncology turnaround?
Regeneron Melanoma Trial: -11.5% Plunge After Phase 3 Shock
Can the Regeneron Melanoma Trial setback derail the biotech’s oncology growth story, or will upcoming data flip the narrative?
Eli Lilly Acquisition Boom: $2.3B Ajax Oncology Shock
Is the latest Eli Lilly Acquisition of Ajax Therapeutics a smart oncology pivot or a risky $2.3 billion side bet?
Eli Lilly Acquisition Boom: Multi‑Billion Cancer and Obesity Bet
Can the latest Eli Lilly Acquisition in next‑gen cancer therapy really justify its sky‑high valuation beyond the obesity drug boom?
Merck Terns Acquisition $6.7B Surge as Keytruda Cliff Nears
Can the Merck Terns Acquisition really plug the looming Keytruda revenue gap or is $6.7 billion just a high-risk oncology bet?
BioNTech Leadership Change: -17.9% Crash After Billion-Euro Loss
Can BioNTech’s surprise leadership change and deepening losses turn a Covid-era star into a long-term oncology value play or a value trap? How did markets react to BioNTech…